
    
      This is a randomized, double-blind, placebo-controlled, parallel-group, phase III study to
      assess the efficacy and safety of 8-week treatment of two fixed doses of Vortioxetine (Lu
      AA21004; 10 or 20 mg/day) in Japanese participants with major depressive disorder (MDD).
    
  